Analysts downwardly revised their ratings and price targets on Brocade Communications Systems, Inc. (BRCD), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), and Wynn Resorts, Limited (WYNN)
Analysts are weighing in on tech stock
Brocade Communications Systems, Inc. (NASDAQ:BRCD), drugmaker
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and gaming giant
Wynn Resorts, Limited (NASDAQ:WYNN). Here's a quick roundup of today's bearish brokerage notes on BRCD, TEVA, and WYNN.
- BRCD is down 4.2% at $9.38, after having its rating downgraded to "underperform" at Baird -- which likewise cut its price target to $8 from $10. However, the shares have still come a long way since their May lows, rallying more than 23%. Speaking more generally, the brokerage bunch is on the fence when it comes to Brocade Communications Systems, Inc. While three analysts do sport "strong buy" endorsements, 13 maintain lukewarm "hold" opinions and one other has handed out a "strong sell."
- TEVA is reportedly set to raise $20-$25 billion via a bond sale next week, which will be used to finance its purchase of Allergan plc's (NYSE:AGN) generic drugs business. Jefferies and Oppenheimer, meanwhile, slashed their respective price targets to $69 and $72. At last check, Teva Pharmaceutical Industries Ltd is slightly lower at $54.45. Longer term, the shares have surrendered 17% of their value in 2016. Options traders are holding out high hopes, based on data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Specifically, over the past two weeks, traders have bought to open 3.72 TEVA calls for each put, a ratio that ranks in the top quartile of its annual range.
- WYNN saw its rating lowered to "neutral" from "overweight" at J.P. Morgan Securities, which also cut its price target to $94 from $101. As a result, the stock is off 2.7% at $92.28, but remains over 33% higher year-to-date. Today's downgrade is par for the course when it comes to Wynn Resorts, Limited. Despite the stock's long-term outperformance, eight of 13 analysts sport "hold" or worse recommendations. Plus, WYNN's consensus 12-month price target of $101.14 represents a modest 10% premium to current levels.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!